Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam
NCT ID: NCT00319605
Last Updated: 2012-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
600 participants
OBSERVATIONAL
2006-04-30
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00643500
A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
NCT00150709
Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures
NCT00419393
Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).
NCT00291655
An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy
NCT01506882
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levetiracetam
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helena Marin Muñoz, MD
Role: STUDY_DIRECTOR
UCB Pharma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
A Coruña, , Spain
Alcalá de Henares, , Spain
Alcázar de San Juan, , Spain
Alcorcón, , Spain
Alicante, , Spain
Alzira Valencia, , Spain
Ávila, , Spain
Badajoz, , Spain
Barcelona, , Spain
Benidorm, , Spain
Cadz, , Spain
Castellon, , Spain
Cáceres, , Spain
Cuenca, , Spain
Elda, , Spain
Eliana, , Spain
Girona, , Spain
Granada, , Spain
Guadalajara, , Spain
Hospitalet Del Llobregat, , Spain
La Roca, , Spain
Langreo, , Spain
Las Palmas, , Spain
Las Palmas de Gran Canaria, , Spain
León, , Spain
Lleida, , Spain
Lorca Murcia, , Spain
Lugo, , Spain
Madrid, , Spain
Manzanares, , Spain
Manzanares Ciudad Real, , Spain
Mataró, , Spain
Málaga, , Spain
Merida Badajoz, , Spain
Móstoles, , Spain
Murcia, , Spain
Oviedo, , Spain
Palencia, , Spain
Palmar, , Spain
Pamplona, , Spain
Pontevedra, , Spain
Puerto del Rosario, , Spain
Sabadell, , Spain
Salamanca, , Spain
San Fernando, , Spain
Santa Cruz de Tenerife, , Spain
Seville, , Spain
Terrassa, , Spain
Teruel, , Spain
Toledo, , Spain
Valencia, , Spain
Vigo Pontevedra, , Spain
Zamora, , Spain
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N01242
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.